TITAN PHARMACEUTICALS INC — Director's Dealing 2016

Feb 2, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TITAN PHARMACEUTICALS INC (TTNP)
CIK: 0000910267
Period of Report: 2016-02-02

Reporting Person: BHONSLE SUNIL (President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-02-02	Option to Purchase Common Stock	$5.10	A	89100	Acquired	2026-02-02	Common Stock (89100)	Direct

Footnotes

F1: The options vest in 24 equal monthly installments commencing on the grant date.